Related Experiment Videos
Cerebral blood flow mapping using stable xenon-enhanced CT in sickle cell cerebrovascular disease
Y Numaguchi1, J S Haller, J R Humbert
1Department of Radiology, Tulane University Medical Center, New Orleans, Louisiana.
Insights
Xenon-CT flow mapping accurately assesses cerebral blood flow (CBF) in sickle cell cerebrovascular disease (SCCVD). MR imaging alone cannot fully predict flow depletion, highlighting Xenon-CT
Area of Science:
- Neurology
- Radiology
- Pediatrics
Background:
- Sickle cell cerebrovascular disease (SCCVD) poses significant risks for stroke.
- Accurate assessment of cerebral blood flow (CBF) is crucial for managing SCCVD.
- Current imaging modalities may not fully capture the extent of hemodynamic compromise.
Purpose of the Study:
- To evaluate the efficacy of Xenon-CT flow mapping in assessing CBF in pediatric SCCVD patients.
- To compare Xenon-CT findings with conventional MRI and CT scans.
- To determine if Xenon-CT can aid in selecting patients for hypertransfusion therapy.
Main Methods:
- Xenon-CT flow mapping was used to examine CBF in 25 patients with SCCVD.
- Brain CT and MR imaging findings were correlated with Xenon-CT results.
- Analysis focused on the correlation between CBF defects and infarctions identified on MRI.
Main Results:
- Xenon-CT CBF defects correlated well with MR-detected cortical infarctions, though defects were sometimes larger.
- Abnormal CBF was observed near infarctions in 72% of patients with deep watershed or basal ganglia infarctions.
- Decreased CBF was detected in children with normal-appearing MR images, indicating limitations of MRI alone.
Conclusions:
- Xenon-CT flow mapping is a safe and reliable method for evaluating CBF in SCCVD.
- MR imaging alone is insufficient for accurately predicting the extent of flow depletion.
- Xenon-CT has potential for guiding hypertransfusion therapy and monitoring treatment in pediatric SCCVD.
Abstract:
The cerebral blood flow (CBF) of 25 patients with sickle cell cerebrovascular disease (SCCVD) was examined using a Xenon-CT flow mapping method. Brain CT and MR findings were correlated with those of the Xenon-CT flow studies. CBF defects on Xenon-CT correlated reasonably well with the areas of cortical infarctions on the MR images, but in 27% of the cases, flow defects were slightly larger than the areas of infarctions on the MR images. In deep watershed or basal ganglia infarctions, abnormal CBF was noted about the cerebral cortex near infarctions in 72% of the patients, regardless of infarction sizes on the MR images. However, decreased CBF was recognized in 4 of the 9 children whose MR images were virtually normal. Thus, the extent of flow depletion cannot be predicted accurately by MR imaging alone. Xenon-CT flow mapping proved a safe and reliable procedure for evaluation of the CBF of patients with SCCVD. Although this study is preliminary, it may have a potential in selecting patients for hypertransfusion therapy, as a noninvasive test and for following children with SCCVD during their therapy. Careful correlation of results of CBF with those of MR imaging or of CT is important for objective interpretations of flow mapping images.